1. Introduction {#sec1-ijerph-15-01558}
===============

Head and neck squamous cell carcinomas (HNSCCs) represent a preventable pathology which continues to be an important factor of morbidity with high mortality rates at global level \[[@B1-ijerph-15-01558],[@B2-ijerph-15-01558]\], with over 600,000 new cases detected each year \[[@B3-ijerph-15-01558],[@B4-ijerph-15-01558]\], and a mortality rate of around 50% \[[@B5-ijerph-15-01558]\]. HNSCCs have as common localizations the oral cavity, oropharynx, hypopharynx, and larynx \[[@B1-ijerph-15-01558],[@B5-ijerph-15-01558],[@B6-ijerph-15-01558]\].

An important aspect in prevention and treatment is related to genetic and environmental components \[[@B2-ijerph-15-01558],[@B7-ijerph-15-01558],[@B8-ijerph-15-01558]\]. While the acquired genetic factors cannot be controlled in their early steps of mutation accumulation, environmental exposure can significantly affect the pathogenesis and the prognosis of these patients \[[@B8-ijerph-15-01558],[@B9-ijerph-15-01558]\]. The major environmental components are tobacco smoking, betel quid chewing, alcohol consumption, and poor oral hygiene and infections, alongside other specific dietary habits or specific pollutant exposure \[[@B6-ijerph-15-01558],[@B7-ijerph-15-01558],[@B10-ijerph-15-01558],[@B11-ijerph-15-01558]\]. The totality of risk factors are integrated into the exposome \[[@B12-ijerph-15-01558]\], this being an important step in the evaluation of internal and external exposure, generally related to the co-occurrence of multiple toxic environmental agents \[[@B13-ijerph-15-01558]\]. Usually, the effect of co-occurrence is much more dramatic than that of the single exposure \[[@B13-ijerph-15-01558]\].

Microarray data are provided by large consortium programs such as The Cancer Genome Atlas (TCGA), offering new possibilities and a better understanding of the role of genes in different cancers \[[@B2-ijerph-15-01558],[@B14-ijerph-15-01558]\]. Analysis of altered gene expression signatures is used in a wide range of pathologies for achieving relevant information with prognostic value \[[@B15-ijerph-15-01558]\]. The altered transcriptomic signatures can be integrated in multiple biological pathways, thus leading to a better comprehension of the fundamental mechanisms that are related to pathological processes influenced by smoking, and can be used for the selection of optimal therapy \[[@B16-ijerph-15-01558],[@B17-ijerph-15-01558]\].

We anticipate that smoking affects molecular mechanisms, including transcriptomic patterns; therefore, we performed a TGCA data analysis in order to identify specific transcriptomic alterations in smoking versus non-smoking patients with head and neck cancer. These data provide a unique opportunity to study the potential oncogenic role of tobacco smoking; furthermore, based on the human papilloma virus (HPV)16 status and its effects on gene expression patterns, we intend to find whether these patients have different gene expression landscapes for the selected exposome components, or for the co-occurrence of these two important components of the exposome.

2. Materials and Methods {#sec2-ijerph-15-01558}
========================

2.1. The Cancer Genome Atlas Gene Expression Data for Head and Neck Squamous Cell Carcinomas {#sec2dot1-ijerph-15-01558}
--------------------------------------------------------------------------------------------

The data were downloaded from the University of California Santa Cruz (USCS) Genome Browser \[[@B18-ijerph-15-01558]\] as a gene expression data matrix containing log~2~ transformed, normalized gene expression data for 519 tumor and 43 normal tumor-adjacent tissue samples (from 13 females and 30 males) and generated by RNA sequencing. [Table 1](#ijerph-15-01558-t001){ref-type="table"} contains the demographic and clinical characteristics of the 519 patients that the tumor tissues were collected from, including clinical stages, information related to TNM (T: tumor, N: node, Mx: metastases), smoking history, and tumor localization.

The initial differential expression analysis was performed on the entire group of samples, namely 519 HNSCC tumors and 43 tumor-adjacent normal tissues. Further analyses were conducted on groups of patients divided according to their smoking status at the moment of sample collection: current smokers, quitters (also known as reformed smokers or ex-smokers), and never smokers.

Differential expression analysis was performed using the Gene Spring GX v.13.0 software from Agilent Technologies (Santa Clara, CA, USA), using the "volcano plot" module, and applying a fold change cut-off of ±2, moderated t-test and false discovery rate (FDR) correction. The bioinformatics analyses for differential expression were performed in the case of tumor tissue (*n* = 519) versus normal tissue (*n* = 43), and different comparisons were made based on smoking status, such as current smoking (*n* = 174) versus never smoked (*n* = 118), having quit smoking (*n* = 209) versus never smoked (*n* = 118), and finally for currently smoking (*n* = 174) versus having quit smoking (*n* = 209).

2.2. Molecular Classification for Gene Expression {#sec2dot2-ijerph-15-01558}
-------------------------------------------------

Signature was performed using different online tools, such as String version 10.5 \[[@B19-ijerph-15-01558]\], Kyoto Encyclopedia of Genes and Genomes (KEEG) pathways \[[@B20-ijerph-15-01558]\], PantherDB \[[@B21-ijerph-15-01558]\] and miRnet data base \[[@B22-ijerph-15-01558]\].

2.3. Survival Analysis {#sec2dot3-ijerph-15-01558}
----------------------

Kaplan--Meier survival analysis was performed to investigate the survival distribution between selected groups based on the smoking status using Graph Pad Prism software (Version 6, Graph Pad software Inc., San Diego, CA, USA). A plot of the Kaplan--Meier analysis with the selected groups based on smoking status was performed.

3. Results {#sec3-ijerph-15-01558}
==========

3.1. Differential Gene Expression in Tumor Tissues Versus Normal Tissues for Head and Neck Squamous Cell Carcinomas {#sec3dot1-ijerph-15-01558}
-------------------------------------------------------------------------------------------------------------------

Global gene expression was evaluated in tumor tissues (*n* = 519) versus normal tissues (*n* = 43), where we identified 1216 upregulated genes and 1751 downregulated genes considering as cut-off the fold change (FC) value of ±2 and *p*-value ≤0.001 (Benjamini--Hochberg correction). Based on the KEGG classification, most of the upregulated genes belong to the extracellular matrix ECM--receptor interaction, focal adhesion, the PI3K (Phosphoinositide 3-kinase) --Akt (Protein kinase B) signaling pathway, or cell cycle regulation, while downregulated genes are involved in altered pathways belonging to drug metabolism cytochrome P450, chemical carcinogenesis and metabolism of xenobiotic by cytochrome P450. We also generated a map describing interconnections of the altered genes with specific targeting miRNAs (microRNAs) in [Figure 1](#ijerph-15-01558-f001){ref-type="fig"}, using the miRnet database.

3.2. Differential Gene Expression Levels in Smokers Compared with Non-Smokers or Ex-Smokers in Head and Neck Squamous Cell Carcinomas {#sec3dot2-ijerph-15-01558}
-------------------------------------------------------------------------------------------------------------------------------------

In order to evaluate the transcriptomic alterations related to smoking in the tumor tissues, we performed multiple comparisons. In the first analysis we compared the gene expression pattern between current smokers and patients who had never smoked, identifying 119 altered transcripts (9 downregulated genes and 110 upregulated) ([Table 2](#ijerph-15-01558-t002){ref-type="table"}). The second analysis compared the gene expression pattern between ex-smokers and patients who had never smoked, revealing 24 altered transcripts (22 upregulated genes and 2 downregulated). The String network is presented in [Figure 2](#ijerph-15-01558-f002){ref-type="fig"}A, for the 20 common upregulated genes for the group of ex-smokers vs. never smoked, and current smokers vs. never smoked, respectively. The third analysis compared the gene expression pattern between current smokers versus those who had quit, revealing 15 overexpressed genes, with the String network displayed in [Figure 2](#ijerph-15-01558-f002){ref-type="fig"}A; the genes are not connected in specific networks. [Figure 2](#ijerph-15-01558-f002){ref-type="fig"}B shows downregulated genes, presented as Venn diagrams for the analyzed groups (current smokers, ex-smokers, non-smokers), and emphasizes a signature in the ex-smokers group, revealing a panel of genes with an altered expression level event after quitting smoking in HNSCC patients.

In [Figure S1](#app1-ijerph-15-01558){ref-type="app"}, the String Network was generated for the altered signature in the case of smoking versus non-smoking, showing that most genes are involved in the metabolism of xenobiotics by cytochrome P450.

3.3. Molecular Classification for Altered Gene Expression Signature in Smoking versus Never Smoking Head and Neck Squamous Cell Carcinomas Patients {#sec3dot3-ijerph-15-01558}
---------------------------------------------------------------------------------------------------------------------------------------------------

In order to perform the classification of the 119 altered genes in smoking versus never smoking HNSCC patients we used different online tools, such as String database \[[@B19-ijerph-15-01558]\] KEGG pathways \[[@B20-ijerph-15-01558]\] and PantherDB \[[@B21-ijerph-15-01558]\].

The String network for the modified gene expression is presented in [Figure 3](#ijerph-15-01558-f003){ref-type="fig"}A, and the KEGG classification in [Figure 3](#ijerph-15-01558-f003){ref-type="fig"}B. In the KEGG pathways classification, most of the genes are related to cellular metabolism, emphasizing the activation of detoxification pathways, chemical carcinogenesis, or drug metabolism. Gene ontology classification based on molecular function and biological processes is presented in [Table 3](#ijerph-15-01558-t003){ref-type="table"}.

3.4. Effect of Smoking on Head and Neck Squamous Cell Carcinomas Stages {#sec3dot4-ijerph-15-01558}
-----------------------------------------------------------------------

To evaluate potential alteration of gene expression, specific for early stages to advanced tumor status, we compared the molecular profiles of tumor tissue in smoking versus non-smoking, according to tumor stages. Results from the computation of specific gene expressions for current smokers versus never smokers on HNSCC stages identified stage-specific gene expression signatures. The data presented as Venn diagrams illustrate the common and different overexpressed and downregulated genes ([Figure 4](#ijerph-15-01558-f004){ref-type="fig"}A,B), while the network created using the String tool for the downregulated genes in the case of current smokers versus never smokers on HNSCC stage 1, revealed 32 genes involved in cell cycle regulation ([Figure 4](#ijerph-15-01558-f004){ref-type="fig"}C).

To address the probable alteration of gene expression as an effect of advanced tumor status, we restricted the gene ontology classification of smoking versus non-smoking only for stage 1 tumors. Gene ontology based on the altered signature of smoking versus never smoking for stage 1 HNSCC is illustrated in [Table 4](#ijerph-15-01558-t004){ref-type="table"}.

3.5. Evaluation of Gene Expression Signature Based on Human Papilloma Virus 16 Status with/without Correlation with Smoking in Head and Neck Squamous Cell Carcinomas Patients {#sec3dot5-ijerph-15-01558}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Using the same TCGA data, we performed a new analysis which allowed the identification of a signature composed of 2087 genes (1143 downregulated and 844 upregulated genes) that discriminates HPV16-induced HNSCC from their HPV-negative counterparts, comprising a patient cohort of 37 patients HPV-positive (HPV+) for subtype 16 and 72 HPV-negative (HPV−) patients. Using the miRnet data base, an analysis of the altered transcripts revealed the most relevant interconnected miRNAs and the most significantly altered pathways ([Figure 5](#ijerph-15-01558-f005){ref-type="fig"}).

A differential expression level comparison was performed, taking into consideration as reference group the nonsmoker patients negative for HPV (HPV− Smoke−), represented by 32 cases, while the other three analyzed groups were represented by smoking patients that were HPV-positive (HPV+ Smoke+, 11 cases), nonsmoking patients that were HPV-positive (HPV+ Smoke−), and smoking patients that were HPV-negative (Smoke+ HPV−, 11 patients). The heat map depicted in [Figure 6](#ijerph-15-01558-f006){ref-type="fig"}A illustrates a specific signature in each analyzed group and in [Table 5](#ijerph-15-01558-t005){ref-type="table"} being presented GO classification for the altered expression signature identified based on HPV-16 status.

Regarding the overexpressed genes, we observed a common signature represented by 724 genes in the case of the HPV+ versus HPV−, and the group (HPV+ Smoke−) versus (Smoke− HPV−); based on the KEGG classification, these genes are related to the ECM--receptor interaction, focal adhesion, and PI3K--Akt signaling ([Figure 6](#ijerph-15-01558-f006){ref-type="fig"}B). We also identified 374 genes specifics for HPV+ versus HPV−, and 309 genes specific for the HPV+ Smoke− group ([Figure 6](#ijerph-15-01558-f006){ref-type="fig"}B). In addition, 507 common genes were identified for the overexpressed genes involved in DNA replication and cell cycle, as obtained by KEGG classification ([Figure 6](#ijerph-15-01558-f006){ref-type="fig"}C).

3.6. Survival Prognosis Analysis Related to Smoking Status in Head and Neck Squamous Cell Carcinomas Patients {#sec3dot6-ijerph-15-01558}
-------------------------------------------------------------------------------------------------------------

The overall survival of HNSC patients related to three different groups based on smoking status: current smoker (*n* = 174), ex-smoker (*n* = 209), and never-smoking groups (*n* = 118) are presented in [Figure S2](#app1-ijerph-15-01558){ref-type="app"}. Also, survival analysis was performed in the case of HPV16+ (*n* = 72) versus HPV16-- group (*n* = 37), observing a slightly increased survival rate in HPV− patients compared to HPV+ cases.

4. Discussion {#sec4-ijerph-15-01558}
=============

The HNSCC disease etiology is complex, being related to genetic background and exposome, where smoking and viral infection are two important players in its causality \[[@B3-ijerph-15-01558],[@B18-ijerph-15-01558],[@B23-ijerph-15-01558],[@B24-ijerph-15-01558],[@B25-ijerph-15-01558],[@B26-ijerph-15-01558],[@B27-ijerph-15-01558]\]. HPV and smoking converge in more aggressive diseases through complex altered pathways (particularly those related to xenobiotic metabolism \[[@B23-ijerph-15-01558],[@B28-ijerph-15-01558],[@B29-ijerph-15-01558]\]) as observed in the presented data, with potentially important clinical implications. At the same time, smoking patients have a reduced overall survival when compared to non-smoking groups \[[@B30-ijerph-15-01558],[@B31-ijerph-15-01558]\]; in our case, we can observe a slightly increased survival rate in the non-smoking group, with no statistical significance. The study of Osazuwa--Peters et al. shows that the survival rate is almost double in the non-smoking versus smoking group with HNSCC \[[@B32-ijerph-15-01558]\].

The overall variation in gene expression profiles for patients who quit smoking versus those who never smoked, and current smokers versus those who quit, was different when comparing tumors with normal tumor adjacent samples. The most significant differences were observed in the case of smoking versus never smoking. These observations are sustained by similar studies \[[@B33-ijerph-15-01558],[@B34-ijerph-15-01558],[@B35-ijerph-15-01558]\]. A set of 49 differentially expressed genes were detected based on smoking status, targeting NFkB-related pathways \[[@B36-ijerph-15-01558]\]. In comprehensive genomic characterization, we showed that most of the altered genes are related to the regulation of mutated TP53 and cell cycle progression \[[@B37-ijerph-15-01558]\]. A study similar to ours emphasized the important role of xenobiotic metabolizing enzymes in several cancer types like bladder \[[@B38-ijerph-15-01558]\] and lung cancer \[[@B39-ijerph-15-01558]\] or leukemia \[[@B40-ijerph-15-01558]\]; cytochrome (CY) P450 enzymes such as CYP1A1 are activated in the case of the smoking group as compared to never smokers \[[@B41-ijerph-15-01558]\]. Xenobiotic metabolizing enzymes CYP1A1 and CYP1B1 were observed also in a cellular model of oral leukoplakia \[[@B42-ijerph-15-01558]\]. The metabolic detoxification pathways have an important role in chemotherapeutics metabolism \[[@B42-ijerph-15-01558]\], affecting the response to therapy in smoking groups. The negative effects can be counteracted by chemopreventive agents \[[@B43-ijerph-15-01558],[@B44-ijerph-15-01558],[@B45-ijerph-15-01558],[@B46-ijerph-15-01558]\].

Our study demonstrated the complex biologic effects of smoking through the analysis related to the effect of smoking on HNSCC stages, particularly for stage 1, emphasizing the altered pathways leading to carcinogenesis. In the case of gene expression signatures in smoking versus never smoking for stage 1 HNSCC patients, using the PantherDB online tool we observed an important number of representative transcripts that are responsible for biological adhesion, including for early stages (*DLL3*, *CDH17*, *TINAGL1*, *STRC*, *PCDHAC2*, *PCDHB13*, *TNR*, *PCDHGB6*, *PCDHGA9*, *PLXNB3*). The same analysis identified 32 downregulated genes related to cell cycle regulation. A cell culture-based study on human placental cells using cigarette smoke extracts showed alterations in cell cycle, cell migration, and endocrine activity \[[@B44-ijerph-15-01558],[@B47-ijerph-15-01558]\], sustaining our findings. Alterations of these vital genes denote a frequent mechanism essential for the susceptibility to a variety of smoking-induced diseases \[[@B48-ijerph-15-01558]\]. These adhesion molecules are retrieved in the circulatory system and not only at tumor sites, especially in advanced stages \[[@B49-ijerph-15-01558],[@B50-ijerph-15-01558],[@B51-ijerph-15-01558]\]. These adhesion effectors and angiogenic markers could thus be used as biomarkers of invasion and metastasis \[[@B49-ijerph-15-01558],[@B50-ijerph-15-01558],[@B52-ijerph-15-01558],[@B53-ijerph-15-01558],[@B54-ijerph-15-01558],[@B55-ijerph-15-01558]\]. Immune and inflammation-related genes may provide a better understanding of the mechanisms through which tobacco smoking causes disease \[[@B56-ijerph-15-01558]\], as well as the possible benefits of immune agonist therapy. A previous study showed that tumors with a genetic smoking pattern had decreased immune infiltration, connected with an unfavorable survival rate \[[@B57-ijerph-15-01558]\]. It was shown that the circulating immune markers of inflammation could mirror the overall immune and inflammatory cancer-promoting microenvironment \[[@B58-ijerph-15-01558],[@B59-ijerph-15-01558]\], and may suggest probable etiologic mechanisms related to smoking-induced diseases, particularly in HNSCC. In our case, the altered immune and inflammatory response genes for stage I smoking vs. nonsmoking identified a panel of 13 genes obtained by PantherDB classification on biological processes (*CCL26*, *TRAF5*, *XCL1*, *BLK*, *DLL3*, *MAPK8IP2*, *CD1B*, *CD1E*, *CRYAB*, *GPX3*, *CCL22*, *LHX4*, *ULBP1*). Smoking also affects immunity in the oral cavity and promotes oral cavity diseases, including oral cancer \[[@B59-ijerph-15-01558]\]; hence, there is no doubt that immune microenvironment of HNSCC significantly affects the response to therapy \[[@B60-ijerph-15-01558]\].

The global gene expression signatures show the interaction between genetics and exposure characteristics, making the subtraction of a single agent effect related to HNSCC very difficult; in spite of this we were able to demonstrate that the transcriptomic pattern is highly influenced by tobacco smoking and HPV status. In the case of HPV+ HNSCCs, the mutational and transcriptomic pattern appeared similar to that of cervical cancer, with a higher mutation incidence in the PI3K pathway and DNA repair genes \[[@B61-ijerph-15-01558]\]. For transcriptomic pattern, altered genes implicated in cell cycle, apoptosis, inflammatory response, DNA replication and repair, or other important transcription factors involved in transcription regulation were revealed \[[@B47-ijerph-15-01558]\]. Gene expression characterization in HPV+ tumors can be used to predict response to therapy, and this information could be used for better tailored therapies \[[@B62-ijerph-15-01558]\]. Our data sustain the idea that HPV-related HNSCC represents a distinct entity, and that current treatment options are not responding to the needs of these patients \[[@B47-ijerph-15-01558],[@B61-ijerph-15-01558]\], proving the necessity for routine testing of HPV in clinical practice \[[@B63-ijerph-15-01558]\] and at the same time underlining the importance of patient stratification based on smoking status or HPV infection.

5. Conclusions {#sec5-ijerph-15-01558}
==============

In conclusion, we demonstrated that smoking and HPV infection make important contributions to the HNSCC genomic portrait; this information can be translated into the creation of better-tailored therapies. A part of the gene expression alteration pattern was the reversible signature related mainly to the metabolism of xenobiotics by cytochrome P450, but some genes remained altered even after quitting smoking. This study emphasizes the utility of HNSCC classification based on smoking status in the management of cancer risk and also in establishing therapeutic options based on the many altered cell signaling pathways that we identified (metabolic detoxification pathways, adhesion cell signaling, or immune and inflammation pathways).

Our pathway analysis was able to identify the most relevant gene expression signature for the smoking HNSCC patients related to xenobiotic metabolizing enzymes, which might affect the response to therapy. These data support the fact that smoking is a major risk factor for HNSCC outcomes and that smoking cessation therapy should be a part of standard HNSCC care. From a research viewpoint, these results emphasize the importance of environmental toxic agent exposure in corroboration with genetic background.

Since a wide range of factors affect gene expression, it is very likely that not all relevant gene transcripts were identified, and some genes with altered expression levels may not have been confirmed; however, these data represent an important starting point for new investigations. Future studies could examine other complexities of the transcriptome in relation with other environmental carcinogens. Regarding the exposome, is difficult to analyze single exposures due to the fact that for most cases a co-occurrence of toxic elements is observed.

The following are available online at <http://www.mdpi.com/1660-4601/15/7/1558/s1>.
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![The interconnected genes with specific miRNAs using miRnet \[[@B22-ijerph-15-01558]\] involved in focal adhesion, extracellular matrix (ECM)--receptor interaction, or pathways in cancer interconnected with targeting microRNAs (miRNAs).](ijerph-15-01558-g001){#ijerph-15-01558-f001}

![Venn diagram used for overlapping the altered gene expression pattern in the case of the three studied groups. Common and specific gene expression signatures for the three groups of HNSCC (head and neck squamous cell carcinomas) patients: non-smokers, ex-smokers, and smokers. (**A**) For the case of overexpressed genes, 20 common genes from non-smokers vs. smokers and ex-smokers vs. smokers, integrated as network using String, version 10.5) \[[@B19-ijerph-15-01558]\]; (**B**) The case of downregulated genes; (**C**) Heat maps for the expression level for the three HNSCC patient groups (current smokers, quitters, non-smokers), in dark blue being presented the downregulated genes and in red those overexpressed genes, generated using Gene Spring version 13.0.](ijerph-15-01558-g002){#ijerph-15-01558-f002}

![Gene network generated using Sting program; (**A**) Network of the interconnected genes; (**B**) KEGG (Kyoto Encyclopedia of Genes and Genomes) classification based on the altered signature in smoking versus never-smoking HNSCC patients.](ijerph-15-01558-g003){#ijerph-15-01558-f003}

![Venn diagram overlapping the (**A**) overexpressed and (**B**) downregulated genes based on a specific analysis of current smokers versus never smokers with HNSCC stage 1, 2, 3, and 4; (**C**) String Network for the case of downregulated genes in current smokers versus never smokers in HNSCC stage 1, where the genes involved in cell cycle regulation are highlighted in red.](ijerph-15-01558-g004){#ijerph-15-01558-f004}

![The interconnected genes with specific miRNAs using miRnet \[[@B22-ijerph-15-01558]\] involved in focal adhesion, ECM--receptor interaction or gap junction.](ijerph-15-01558-g005){#ijerph-15-01558-f005}

![Gene expression signature based on HPV16 status with/without correlation with smoking in HNSCC patients. (**A**) Heat maps representing the expression level in the HNSCC patient group based on smoking and HPV status. For nonsmoking and HPV16-negative patients (Smoking− HPV−, *n* = 32), we had Smoking+ HPV− (*n* = 11), Smoking+ HPV+ (*n* = 11), Smoking− HPV+ (*n* = 11), in dark blue being presented the downregulated genes and in red those overexpressed genes, generated using Gene Spring version 13.0. (**B**) Venn diagram showing the differential signature in the case of the overexpressed genes highlighting the main altered pathways as displayed by KEGG classification. (**C**) Venn diagram to emphasize that the differential signature in the case of the overexpressed genes underlines the main altered pathways as obtained from String Network and KEGG (Kyoto Encyclopedia of Genes and Genomes) classification, with red dots showing the genes involved in cytokine--cytokine receptor interaction and blue dots the cell adhesion molecules.](ijerph-15-01558-g006){#ijerph-15-01558-f006}

ijerph-15-01558-t001_Table 1

###### 

Succinct presentation of the TCGA characteristics for patients diagnosed with HNSCCs used for gene expression analysis. Head and neck squamous cell carcinomas: HNSCCs, T: tumor, N: node, M0 no metastasis, Mx: metastases presence; HPV: human papilloma virus; TCGA: The Cancer Genome Atlas.

  Clinical Parameters                              Patients (*n* = 519)   Females/Males
  ------------------------------- ---------------- ---------------------- ---------------
  Sex                             Females          134                    
  Males                           374                                     
  Undeclared                      11                                      
  Age                             Median, range    61, 19--90             
  Median, range males             59, 19--88                              
  Median, range females           64.5, 24--90                            
  Undeclared                      11                                      
  Clinical stage                  1                20                     9/11
  2                               98               33/65                  
  3                               101              26/75                  
  4                               275              64/211                 
  Unknown                         25                                      
  Clinical TNM                    T1N0M0           18                     7/11
  T1N1M0                          5                2/3                    
  T1N2M0                          7                1/6                    
  T1N2M1                          1                -/1                    
  T1NxM0                          2                2/-                    
  T1N0M0                          96               33/63                  
  T1N0Mx                          1                -/1                    
  T2N1M0                          12               3/9                    
  T2N1Mx                          1                1/-                    
  T2N2M0                          33               6/27                   
  T2N2M1                          1                -/1                    
  T2N2Mx                          3                -/3                    
  T1N3M0                          1                -/1                    
  T2NxM0                          1                -/1                    
  T3N0M0                          58               15/43                  
  T3N0Mx                          1                1/-                    
  T2N1M0                          20               4/16                   
  T3N1M1                          1                1/-                    
  T3N2M0                          46               8/38                   
  T3N2M1                          1                1/-                    
  T3N2Mx                          1                -/1                    
  T3N3M0                          1                -/1                    
  T3NxM0                          2                -/2                    
  T4N0M0                          66               17/49                  
  T4N0Mx                          1                1/-                    
  T4N1M0                          39               13/26                  
  T4N2M0                          62               14/48                  
  T4N2Mx                          1                -/1                    
  T4N3M0                          7                2/5                    
  T4NxM0                          3                -/3                    
  TxN1M0                          1                -/1                    
  TxN2M0                          1                -/1                    
  TxNxMx                          9                -/9                    
  Unknown                         16                                      
  Smoking history                 Smoker           174                    35/139
  Reformed smoker \<15 years      134              26/108                 
  Reformed smoker \>15 years      72               19/53                  
  Reformed, unknown years         2                0/2                    
  Lifelong non-smoker             114              49/65                  
  Unknown                         23                                      
  Anatomic neoplasm subdivision   Alveolar ridge   18                     
  Base of tongue                  27                                      
  Buccal mucosa                   20                                      
  Floor of mouth                  60                                      
  Hard palate                     7                                       
  Hypopharynx                     9                                       
  Larynx                          114                                     
  Lip                             3                                       
  Oral cavity                     71                                      
  Oral tongue                     127                                     
  Oropharynx                      10                                      
  Tonsil                          42                                      
  Unknown                         11                                      
  HPV                             Positive         72                     
  Negative                        37                                      
  Unknown                         410                                     

ijerph-15-01558-t002_Table 2

###### 

Genes with altered expression levels, based on a fold change (FC) ± 2, *p*-value ≤ 0.05 for smoking versus never smoking HNSCC patients.

  Gene          FC (abs)   *p*-Value        Regulation   Gene          FC (abs)   *p*-Value       Regulation
  ------------- ---------- ---------------- ------------ ------------- ---------- --------------- ------------
  *CDKN2A*      −2.59737   0.000603         Down         *EPHA7*       2.39461    0.000111        Up
  *RYR3*        −2.35924   1.45 × 10^−6^    Down         *psiTPTE22*   2.394392   6.22 × 10^−6^   Up
  *KRT2*        −2.31761   0.002097         Down         *POU6F2*      2.393242   3.2 × 10^−6^    Up
  *KCNS1*       −2.31495   0.000321         Down         *SOHLH1*      2.390684   0.000256        Up
  *MYBPC1*      −2.10091   0.046549         Down         *LTF*         2.380863   0.012372        Up
  *ARL14*       −2.08283   0.000138         Down         *MLXIPL*      2.373807   8 × 10^−6^      Up
  *IL13RA2*     −2.05906   8.82 × 10^−5^    Down         *GLI2*        2.372254   6.52 × 10^−7^   Up
  *FLRT3*       −2.02315   0.002341         Down         *NLGN4Y*      2.358872   0.00092         Up
  *PLA2G2F*     −2.01307   0.002746         Down         *PAK7*        2.355639   6.22 × 10^−6^   Up
  *NTS*         5.224654   8 × 10^−6^       Up           *FIBCD1*      2.345015   0.000181        Up
  *RPS4Y1*      4.924049   7.27 × 10^−5^    Up           *GATA4*       2.343389   0.000117        Up
  *UGT1A6*      4.505707   3.3 × 10^−7^     Up           *PANX2*       2.319508   1.31 × 10^−6^   Up
  *UPK1B*       4.336869   4.15 × 10^−5^    Up           *PCYT1B*      2.314619   3.29 × 10^−5^   Up
  *MGST1*       4.296636   4.68 × 10^−7^    Up           *FGF19*       2.31125    3.18 × 10^−5^   Up
  *CYP1A1*      4.269958   5.3 × 10^−13^    Up           *SLC44A4*     2.29202    0.000356        Up
  *C20orf114*   3.985658   0.001123         Up           *SCN2A*       2.28985    0.00011         Up
  *SCGB3A1*     3.985451   3.93 × 10^−5^    Up           *PROM1*       2.2842     0.001556        Up
  *GPR15*       3.913692   2.69 × 10^−15^   Up           *CYorf15A*    2.257771   0.002582        Up
  *DDX3Y*       3.748438   0.000214         Up           *TFPI2*       2.25193    0.000222        Up
  *MUC5B*       3.573662   0.001207         Up           *MSI1*        2.249305   2.06 × 10^−5^   Up
  *CNNM1*       3.508977   3.02 × 10^−8^    Up           *ADD2*        2.237741   6.45 × 10^−5^   Up
  *CES1*        3.41544    1.21 × 10^−5^    Up           *ALDH1A1*     2.234898   0.000377        Up
  *PRAME*       3.289014   0.000277         Up           *ERN2*        2.210954   0.000992        Up
  *GPX2*        3.252181   3.95 × 10^−6^    Up           *LGI3*        2.206128   0.000183        Up
  *CYP26A1*     3.241253   2.07 × 10^−5^    Up           *PRKY*        2.206114   0.002395        Up
  *NR5A1*       3.186291   1.24 × 10^−5^    Up           *SALL1*       2.200458   8.32 × 10^−6^   Up
  *PPP1R1B*     3.18047    1.38 × 10^−5^    Up           *TBX5*        2.194891   8.95 × 10^−6^   Up
  *FGFBP2*      3.156294   2.95 × 10^−6^    Up           *HOXA4*       2.181679   4.15 × 10^−6^   Up
  *SLC13A5*     3.142512   6.04 × 10^−6^    Up           *TNNI3*       2.18105    4.06 × 10^−5^   Up
  *DMBT1*       3.102893   0.000721         Up           *PLUNC*       2.179797   0.009085        Up
  *KRTCAP3*     3.077278   7.92 × 10^−12^   Up           *NGB*         2.177274   0.000323        Up
  *BPIL1*       3.011847   0.002582         Up           *FOLR1*       2.175127   0.000402        Up
  *UGT1A8*      3.00819    1.43 × 10^−5^    Up           *GDA*         2.163271   0.00378         Up
  *PTH2R*       2.849531   2.55 × 10^−5^    Up           *AKR1C3*      2.150982   8.66 × 10^−5^   Up
  *KRT19*       2.812564   0.001704         Up           *AZGP1*       2.142351   0.004176        Up
  *GAL*         2.792954   6.04 × 10^−6^    Up           *CCNA1*       2.138528   0.001642        Up
  *EIF1AY*      2.761805   0.001147         Up           *PCDH19*      2.131033   0.000887        Up
  *WNK2*        2.756387   3.74 × 10^−5^    Up           *GJB7*        2.128482   0.000382        Up
  *B4GALNT4*    2.731352   5.73 × 10^−7^    Up           *WDR72*       2.119921   0.003053        Up
  *RAB3B*       2.721629   2.09 × 10^−7^    Up           *CLDN8*       2.118758   0.001164        Up
  *FAM132A*     2.67193    2.95 × 10^−6^    Up           *CBS*         2.117995   2.03 × 10^−5^   Up
  *HOXA7*       2.666479   3.29 × 10^−5^    Up           *MSMB*        2.117211   0.003146        Up
  *PIGR*        2.652387   0.004096         Up           *CFTR*        2.112852   0.00034         Up
  *BCHE*        2.639082   3.2 × 10^−6^     Up           *NTRK2*       2.112379   0.001737        Up
  *UGT8*        2.635306   5.71 × 10^−5^    Up           *FGF13*       2.108137   2.2 × 10^−5^    Up
  *USP9Y*       2.629508   0.001642         Up           *RPL39L*      2.085114   5.8 × 10^−6^    Up
  *PDIA2*       2.613751   2.12 × 10^−6^    Up           *SLC29A4*     2.079458   4.68 × 10^−7^   Up
  *ZFY*         2.558155   0.0013           Up           *ADH7*        2.07414    0.012696        Up
  *CALB1*       2.545223   0.002413         Up           *PIWIL2*      2.068965   0.000399        Up
  *AKR1C1*      2.540783   7.2 × 10^−6^     Up           *CYP1B1*      2.057724   8.81 × 10^−5^   Up
  *UTY*         2.533913   0.00193          Up           *CPNE7*       2.055357   1.57 × 10^−6^   Up
  *ATP13A5*     2.530633   0.00011          Up           *BRDT*        2.041222   0.001179        Up
  *SLC5A12*     2.504015   2.95 × 10^−6^    Up           *CHGA*        2.033392   2.12 × 10^−5^   Up
  *FOXJ1*       2.491234   0.000516         Up           *ABO*         2.032663   0.001283        Up
  *PRDM13*      2.479601   4.03 × 10^−7^    Up           *STATH*       2.023424   0.020511        Up
  *HORMAD1*     2.437306   0.001219         Up           *SCN9A*       2.018196   0.00048         Up
  *UCHL1*       2.434416   7.96 × 10^−6^    Up           *ADAMTS20*    2.011134   0.000245        Up
  *NPW*         2.41423    6.04 × 10^−6^    Up           *RBM11*       2.010622   4.12 × 10^−5^   Up
  *PNCK*        2.396283   8.83 × 10^−5^    Up           *ZNF556*      2.009657   1.24 × 10^−5^   Up
  *TCF15*       2.007499   4.31 × 10^−5^    Up                                                    
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###### 

Gene ontology (GO) classification based on the gene expression signature in smoking versus never-smoking HNSCC patients using the PantherDB online tool \[[@B21-ijerph-15-01558]\].

  Ontology Function                                            Type                            No. Molecules   Percent (%)
  ------------------------------------------------------------ ------------------------------- --------------- -------------
  Molecular function                                           binding (GO:0005488)            33              36.7%
  catalytic activity (GO:0003824)                              30                              33.3%           
  transporter activity (GO:0005215)                            14                              15.6%           
  receptor activity (GO:0004872)                               4                               4.4%            
  signal transducer activity (GO:0004871)                      4                               4.4%            
  structural molecule activity (GO:0005198)                    3                               3.3%            
  translation regulator activity (GO:0045182)                  1                               1.1%            
  antioxidant activity (GO:0016209)                            1                               1.1%            
  Biological process                                           cellular process (GO:0009987)   48              28.1%
  metabolic process (GO:0008152)                               32                              18.7%           
  biological regulation (GO:0065007)                           23                              13.5%           
  developmental process (GO:0032502)                           16                              9.4%            
  response to stimulus (GO:0050896)                            15                              8.8%            
  multicellular organismal process (GO:0032501)                13                              7.6%            
  localization (GO:0051179)                                    8                               4.7%            
  cellular component organization or biogenesis (GO:0071840)   7                               4.1%            
  biological adhesion (GO:0022610)                             4                               2.3%            
  locomotion (GO:0040011)                                      3                               1.8%            
  immune system process (GO:0002376)                           1                               0.6%            
  reproduction (GO:0000003)                                    1                               0.6%            
  Protein class                                                transporter (PC00227)           10              13.5%
  hydrolase (PC00121)                                          9                               12.2%           
  oxidoreductase (PC00176)                                     8                               10.8%           
  transcription factor (PC00218)                               8                               10.8%           
  nucleic acid binding (PC00171)                               7                               9.5%            
  signaling molecule (PC00207)                                 6                               8.1%            
  transferase (PC00220)                                        5                               6.8%            
  enzyme modulator (PC00095)                                   5                               6.8%            
  receptor (PC00197)                                           3                               4.1%            
  extracellular matrix protein (PC00102)                       2                               2.7%            
  cytoskeletal protein (PC00085)                               2                               2.7%            
  transfer/carrier protein (PC00219)                           2                               2.7%            
  cell junction protein (PC00070)                              2                               2.7%            
  lyase (PC00144)                                              1                               1.4%            
  calcium-binding protein (PC00060)                            1                               1.4%            
  defense/immunity protein (PC00090)                           1                               1.4%            
  membrane traffic protein (PC00150)                           1                               1.4%            
  isomerase (PC00135)                                          1                               1.4%            
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###### 

Gene ontology (GO) classification based on the gene expression signature in smoking versus never smoking for stage 1 HNSCC patients using the PantherDB online tool, showing the maximum effect of smoking and the minimum effect of tumor environment.

  Ontology Function                                             Type                             No. Molecules   Percent (%)
  ------------------------------------------------------------- -------------------------------- --------------- -------------
  Molecular function                                            binding (GO:0005488)             1433            37.5%
  catalytic activity (GO:0003824)                               1262                             33.0%           
  transporter activity (GO:0005215)                             429                              11.2%           
  receptor activity (GO:0004872)                                255                              6.7%            
  signal transducer activity (GO:0004871)                       231                              6.0%            
  structural molecule activity (GO:0005198)                     157                              4.1%            
  antioxidant activity (GO:0016209)                             23                               0.6%            
  translation regulator activity (GO:0045182)                   17                               0.4%            
  channel regulator activity (GO:0016247)                       13                               0.3%            
  Biological process                                            cellular process (GO:0009987)    2479            29.5%
  metabolic process (GO:0008152)                                1589                             18.9%           
  biological regulation (GO:0065007)                            911                              10.9%           
  response to stimulus (GO:0050896)                             696                              8.3%            
  localization (GO:0051179)                                     583                              6.9%            
  cellular component organization or biogenesis (GO:0071840)    581                              6.9%            
  developmental process (GO:0032502)                            534                              6.4%            
  multicellular organismal process (GO:0032501)                 523                              6.2%            
  immune system process (GO:0002376)                            146                              1.7%            
  locomotion (GO:0040011)                                       120                              1.4%            
  biological adhesion (GO:0022610)                              110                              1.3%            
  reproduction (GO:0000003)                                     83                               1.0%            
  rhythmic process (GO:0048511)                                 32                               0.4%            
  cell killing (GO:0001906)                                     6                                0.1%            
  Protein class                                                 nucleic acid binding (PC00171)   565             15.2%
  transcription factor (PC00218)                                504                              13.5%           
  hydrolase (PC00121)                                           410                              11.0%           
  receptor (PC00197)                                            355                              9.5%            
  transporter (PC00227)                                         269                              7.2%            
  signaling molecule (PC00207)                                  251                              6.7%            
  transferase (PC00220)                                         240                              6.4%            
  cytoskeletal protein (PC00085)                                192                              5.2%            
  enzyme modulator (PC00095)                                    179                              4.8%            
  oxidoreductase (PC00176)                                      149                              4.0%            
  extracellular matrix protein (PC00102)                        84                               2.3%            
  membrane traffic protein (PC00150)                            83                               2.2%            
  ligase (PC00142)                                              79                               2.1%            
  calcium-binding protein (PC00060)                             72                               1.9%            
  structural protein (PC00211)                                  63                               1.7%            
  isomerase (PC00135)                                           42                               1.1%            
  lyase (PC00144)                                               36                               1.0%            
  defense/immunity protein (PC00090)                            35                               0.9%            
  cell adhesion molecule (PC00069)                              31                               0.8%            
  cell junction protein (PC00070)                               31                               0.8%            
  chaperone (PC00072)                                           24                               0.6%            
  transfer/carrier protein (PC00219)                            19                               0.5%            
  transmembrane receptor regulatory/adaptor protein (PC00226)   11                               0.3%            
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###### 

Gene ontology (GO) classification based on the gene expression signature in HPV16-positive versus HPV16-negative patients using the PantherDB online tool \[[@B21-ijerph-15-01558]\].

  Ontology Function                                             Type                            No. Molecules   Percent (%)
  ------------------------------------------------------------- ------------------------------- --------------- -------------
  Molecular function                                            binding (GO:0005488)            6900            41.1%
  catalytic activity (GO:0003824)                               5156                            30.7%           
  transporter activity (GO:0005215)                             1474                            8.8%            
  receptor activity (GO:0004872)                                1450                            8.6%            
  signal transducer activity (GO:0004871)                       895                             5.3%            
  structural molecule activity (GO:0005198)                     826                             4.9%            
  translation regulator activity (GO:0045182)                   53                              0.3%            
  antioxidant activity (GO:0016209)                             23                              0.1%            
  binding (GO:0005488)                                          6900                            41.1%           
  Biological process                                            cellular process (GO:0009987)   10968           28.1%
  metabolic process (GO:0008152)                                6589                            16.9%           
  biological regulation (GO:0065007)                            4065                            10.4%           
  response to stimulus (GO:0050896)                             3467                            8.9%            
  developmental process (GO:0032502)                            3319                            8.5%            
  multicellular organismal process (GO:0032501)                 2954                            7.6%            
  cellular component organization or biogenesis (GO:0071840)    2626                            6.7%            
  localization (GO:0051179)                                     2125                            5.4%            
  immune system process (GO:0002376)                            975                             2.5%            
  biological adhesion (GO:0022610)                              898                             2.3%            
  locomotion (GO:0040011)                                       668                             1.7%            
  reproduction (GO:0000003)                                     289                             0.7%            
  rhythmic process (GO:0048511)                                 28                              0.1%            
  growth (GO:0040007)                                           27                              0.1%            
  Protein class                                                 hydrolase (PC00121)             2235            13.2%
  nucleic acid binding (PC00171)                                1676                            9.9%            
  signaling molecule (PC00207)                                  1598                            9.5%            
  transcription factor (PC00218)                                1551                            9.2%            
  enzyme modulator (PC00095)                                    1462                            8.7%            
  receptor (PC00197)                                            1324                            7.8%            
  cytoskeletal protein (PC00085)                                987                             5.9%            
  transferase (PC00220)                                         987                             5.9%            
  transporter (PC00227)                                         977                             5.8%            
  oxidoreductase (PC00176)                                      667                             4.0%            
  extracellular matrix protein (PC00102)                        632                             3.7%            
  cell adhesion molecule (PC00069)                              560                             3.3%            
  calcium-binding protein (PC00060)                             362                             2.1%            
  membrane traffic protein (PC00150)                            331                             2.0%            
  cell junction protein (PC00070)                               307                             1.8%            
  defense/immunity protein (PC00090)                            278                             1.6%            
  ligase (PC00142)                                              185                             1.1%            
  structural protein (PC00211)                                  173                             1.0%            
  chaperone (PC00072)                                           157                             0.9%            
  transmembrane receptor regulatory/adaptor protein (PC00226)   147                             0.9%            
  lyase (PC00144)                                               134                             0.8%            
  isomerase (PC00135)                                           66                              0.4%            
  transfer/carrier protein (PC00219)                            63                              0.4%            
